Clinical application of high throughput sequencing technology in central nervous system infection

Clinical application of high throughput sequencing technology in central nervous system infection in neurosurgery

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200065021

Enrollment

Unknown

Registered

2022-10-26

Start date

2022-03-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central nervous system infection

Interventions

Gold Standard:The reference standard was carried out using the Chinese neurosurgery critical care management expert consensus (2020 Edition). The diagnostic criteria are: (1) clinical manifestations:

Index test:Traditional cerebrospinal fluid routine, biochemical and bacterial culture, cerebrospinal fluid pathogenic genome sequencing technology

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. There are clinical manifestations or signs of meningitis, encephalitis or cerebrospinal meningitis; 2. Cerebrospinal fluid properties suggest inflammatory reaction; 3. Complete the detection of tNGS, mNGS and related traditional microbial culture.

Exclusion criteria

Exclusion criteria: 1. Patients who refused lumbar puncture or had lumbar puncture contraindications; 2. Patients with tumor, autoimmune encephalitis and rheumatic immune diseases; 3. Pregnant patients; 4. Other patients not suitable for inclusion in the study.

Design outcomes

Primary

Measure	Time frame
Sensitivity;Specificity;	—

Countries

China

Contacts

Public ContactHongwei Chen

Aviation General Hospital

hongwei12@163.com+86 13581529241

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026